Artificial Intelligence in Assistive Technology

By Michael Awood

October 1, 2023

Assistive Technology devices enhanced by Artificial Intelligence

Artificial Intelligence (AI) has been a game-changer in many sectors, including healthcare. AI has been successful in Assistive Technology, an area that’s always been at the forefront of technology.

AI has the potential to revolutionize AT, as highlighted by the UN Special Rapporteur on the rights of persons with disabilities. It can enhance assistive robots, autonomous wheelchairs, and guidance systems for visually impaired individuals. Speech recognition improvements are improving AT applications, while smart homes can boost independence and well-being.

However, challenges exist. AI systems learn from data “training sets,” and if these sets lack diversity, the technology may not reflect the needs of diverse human experiences. Also, the transparency of the data labelling process and lack of diversity in data collection can lead to biased AI tools. Therefore, AI training sets must include AT users to ensure the technology caters to their needs.

Many of these technologies are still in development and have yet to overcome significant barriers. For example, people with dysarthria are hard for speech recognition systems to understand, and smart wheelchairs have trouble detecting descending stairs.

The healthcare workforce should be trained in using digital products and AI tools to educate future generations. This is part of a broader framework to support these technologies’ development and sustainability.

Regulations, standards, and policies also need to keep pace with technological advancements. The proposed EU legislation has raised concerns among the European Disability Forum as it does not sufficiently address and protect the rights of persons with disabilities, especially when AI is used for access to public and private services.

AI could revolutionize AT, but it’s important to involve AT users and healthcare providers in the development process. This involves talking about the ethical use of these technologies and creating rules and policies to govern them.

Reference url

Recent Posts

EMA CHMP Meeting Highlights
Regulatory Insights from EMA CHMP Meeting Highlights

By HEOR Staff Writer

June 26, 2026

The EMA CHMP Meeting Highlights from 22-25 June 2026 show the committee advancing six new medicines while maintaining rigorous evidentiary standards for complex and rare conditions. Positive opinions covered an inactivated influenza vaccine for adults 50 and older, a levodopa-carbidopa intestinal...
cemdisiran gMG treatment
Breakthrough in cemdisiran gMG treatment Advances Regulatory Landscape

By João L. Carapinha

June 25, 2026

Cemdisiran gMG treatment has cleared a critical hurdle after the FDA and EMA accepted Regeneron’s regulatory submissions for review in anti-AChR antibody-positive generalized myasthenia gravis (gMG). The investigational siRNA therapy targeting complement protein C5 could become the first subcutan...
Trodelvy ADC approval
Advancements in Breast Cancer Treatment Following Trodelvy ADC Approval

By João L. Carapinha

June 25, 2026

The Trodelvy ADC approval by the European Commission delivers the first antibody-drug conjugate approved for first-line use in adults with unresectable or metastatic triple-negative breast cancer who are ineligible for PD-1 or PD-L1 inhibitors. This